“For research use only. Not for human consumption.” The sentence appears on effectively every research peptide listing, and it is widely treated as though it settled a regulatory question. It does considerably less than that.
Where the phrase is actually defined
In United States regulation, research-use-only labelling has a specific home: in vitro diagnostic products. FDA's labelling regulation for IVDs at 21 CFR 809.10(c) sets out the statements to be used for products in the laboratory research phase of development, including the familiar research-use-only wording.
That is a rule about diagnostic products. It is not a general-purpose exemption category that any substance can enter by printing a sentence on a label, and the sector's much broader use of the phrase is an industry convention that borrowed the wording.
What determines regulatory status instead
Under the Federal Food, Drug, and Cosmetic Act, whether something is a drug turns substantially on intended use — what it is represented as being for. Intended use is established by the totality of the evidence about how a product is presented, not by a single disclaimer.
That evidence is broad, and it is not confined to the product page.
- Product page copy, headings and category names.
- Claims about effects, outcomes, or conditions, however phrased.
- Comparisons to approved drugs, or to their indications.
- Search and paid advertising targeting, including the keywords bought.
- Email marketing, social posts and affiliate content.
- Customer service correspondence.
- Presentation choices: dosing-shaped packaging, injection accessories, quantity guidance.
Two things the label does not do
- It does not make an unapproved substance approved. Regulatory status is a property of the substance and its intended use, not of the wording on the vial.
- It does not establish that anything was tested. Research-use labelling carries no analytical implication whatsoever — no purity, identity, sterility or endotoxin result is implied by it.
Adjacent regimes that apply independently
Several other frameworks operate on their own terms and are unaffected by product labelling.
- Compounding. Sections 503A and 503B of the FD&C Act govern compounded preparations, and FDA maintains evaluation categories for bulk drug substances nominated for compounding use. A substance's placement there is independent of how a research supplier labels it.
- Advertising substantiation. FTC requires competent and reliable evidence for health-related claims made in commerce, regardless of any disclaimer.
- Import and customs. Declared use affects admissibility determinations.
- Sport. Anti-doping rules apply to athletes by their own terms, independent of any product labelling.
Reading the label as information
Treated as a claim, research-use-only labelling tells you almost nothing. Treated as a description of scope, it tells you one useful thing: the seller is asserting that the material has not been produced, tested or released against the requirements that apply to products intended for human use.
That is a genuine and substantive statement — it means the manufacturing controls, sterility assurance, and release testing that a human-use product would require have not necessarily been applied. Read that way, the label is informative precisely because of what it disclaims.
Sources
- 21 CFR 809.10 — Labeling for in vitro diagnostic products
- FDA — Compounding and the FD&C Act sections 503A and 503B
- FTC — Health Products Compliance Guidance
- FDA — Warning Letters databasePrimary record of how intended use has been assessed in practice.
This article is informational. It is not medical, legal or financial advice. Editorial policy · Report a correction